{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:06Z","timestamp":1740130266839,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>RA patients are often not in remission due to patient global assessment of disease activity (PtGA) included in disease activity indices. The aim was to assess the lag of patient-reported outcomes (PROs) after remission measured by clinical disease activity index (CDAI) or swollen joint count (SJC28).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>RA patients enrolled in the Ontario Best Practices Research Initiative registry not in low disease state at baseline with at \u22656\u2009months of follow-up, were included. Low disease state was defined as CDAI\u2009\u2264\u200910, SJC28\u2009\u2264\u20092, PtGA\u2009\u2264\u20092cm, pain score\u2009\u2264\u20092cm, or fatigue\u2009\u2264\u20092cm. Remission included CDAI\u2009\u2264\u20092.8, SJC28\u2009\u2264\u20091, PtGA\u2009\u2264\u20091cm, pain score\u2009\u2264\u20091cm, or fatigue\u2009\u2264\u20091cm. Time to first low disease state\/remission based on each definition was calculated overall and stratified by early vs established RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 986 patients were included (age 57.4\u2009(12.9), disease duration 8.3\u2009(9.9)\u2009years, 80% women). The median (95% CI) time in months to CDAI\u2009\u2264\u200910 was 12.4 (11.4, 13.6), SJC28\u2009\u2264\u20092 was 9 (8.2, 10), PtGA\u2009\u2264\u20092cm was 18.9 (16.1, 22), pain\u2009\u2264\u20092cm was 24.5 (19.4, 30.5), and fatigue\u2009\u2264\u20092cm was 30.4 (24.8, 31.7). For remission, the median (95% CI) time in months to CDAI\u2009\u2264\u20092.8 was 46.5 (42, 54.1), SJC28\u2009\u2264\u20091 was 12.5 (11.4, 13.4), PtGA\u2009\u2264\u20091cm was 39.6 (34.6, 44.8), pain\u2009\u2264\u20091cm was 54.7 (43.6, 57.5) and fatigue\u2009\u2264\u20091cm was 42.6 (36.8, 48). Time to achieving low disease state and remission was generally significantly shorter in early RA compared with established RA with the exception of fatigue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Time to achieving low disease state or remission based on PROs was considerably longer compared with swollen joint count. Treating to a composite target in RA could lead to inappropriate changes in DMARDs.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa343","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T19:13:07Z","timestamp":1591989187000},"page":"717-727","source":"Crossref","is-referenced-by-count":1,"title":["Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI)"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"first","affiliation":[{"name":"Divisions of Rheumatology, Epidemiology, and Biostatistics, Department of Medicine, Western University, London, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"Medical Affairs, JSS Medical Research, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Movahedi","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada"},{"name":"Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Cesta","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S","family":"Sampalis","sequence":"additional","affiliation":[{"name":"Medical Affairs, JSS Medical Research, Montreal, QC, Canada"},{"name":"Department of Surgery, McGill University, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada"},{"name":"Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"Department of Medicine, (DOM) and Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for OBRI investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2021020119055731600_keaa343-B1","first-page":"ii11","article-title":"Pathogenesis of bone and cartilage destruction in rheumatoid arthritis","volume":"42(Suppl 2","author":"Goldring","year":"2003","journal-title":"Rheumatology"},{"key":"2021020119055731600_keaa343-B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2021020119055731600_keaa343-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2010.07.004","article-title":"Rheumatoid arthritis progression mediated by activated synovial fibroblasts","volume":"16","author":"Neumann","year":"2010","journal-title":"Trends Mol Med"},{"key":"2021020119055731600_keaa343-B4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The burden of disease in rheumatoid arthritis","volume":"32","author":"Uhlig","year":"2014","journal-title":"Pharmacoeconomics"},{"year":"2017","key":"2021020119055731600_keaa343-B5"},{"key":"2021020119055731600_keaa343-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"year":"2018","key":"2021020119055731600_keaa343-B7"},{"key":"2021020119055731600_keaa343-B8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021020119055731600_keaa343-B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","article-title":"Patient reported outcomes in rheumatoid arthritis clinical trials","volume":"17","author":"Orbai","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2021020119055731600_keaa343-B10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","article-title":"Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions","volume":"71","author":"Studenic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021020119055731600_keaa343-B11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s10067-018-4063-9","article-title":"Influence of the different \u201cpatient global assessment\u201d formulations on disease activity score by different indices in rheumatoid arthritis","volume":"37","author":"Ferreira","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021020119055731600_keaa343-B12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-017-1419-5","article-title":"Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation","volume":"19","author":"Challa","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021020119055731600_keaa343-B13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13075-016-1004-3","article-title":"Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity","volume":"18","author":"Smolen","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021020119055731600_keaa343-B14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.semarthrit.2017.04.008","article-title":"Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis","volume":"47","author":"Ito","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021020119055731600_keaa343-B15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature","volume":"18","author":"Nikiphorou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021020119055731600_keaa343-B16","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/acr.23862","article-title":"Is it time to Banish composite measures for remission in rheumatoid arthritis?","volume":"71","author":"Pope","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2021020119055731600_keaa343-B17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-017-0063-5","article-title":"The patient global assessment of disease activity in rheumatoid arthritis: identification of underlying latent factors","volume":"4","author":"Challa","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2021020119055731600_keaa343-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0b013e3283235ac4","article-title":"Early inflammatory arthritis versus rheumatoid arthritis","volume":"21","author":"Finckh","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"2021020119055731600_keaa343-B19","doi-asserted-by":"crossref","first-page":"e000057","DOI":"10.1136\/rmdopen-2015-000057","article-title":"Rheumatoid arthritis treatment: the earlier the better to prevent joint damage","volume":"1","author":"Monti","year":"2015","journal-title":"RMD Open"},{"key":"2021020119055731600_keaa343-B20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.57.2.88","article-title":"Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study","volume":"57","author":"Munro","year":"1998","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/717\/36167803\/keaa343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/717\/36167803\/keaa343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T04:45:59Z","timestamp":1666932359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/2\/717\/5891916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa343","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,8,13]]}}}